Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

AIDS

Volumn 14, Issue 4, 2000, Pages 397-403

  Ruiz, Lidia ^a,b   Martinez Picado, Javier ^a   Romeu, Joan ^b   Paredes, Roger ^a   Zayat, Mohd Khalil ^a   Marfil, Silvia ^a   Negredo, Eugenia ^b   Sirera, Guillem ^b   Tural, Cristina ^b   Clotet, Bonaventura ^a,b  

^a IrsiCaixa Foundation   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cellular immunity; Chronic HIV infection; HIV drug resistance mutations; Structured treatment interruption; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; STAVUDINE; TETANUS TOXOID; TUBERCULIN; ZIDOVUDINE;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; VERTIGO; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; GENE DELETION; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIREMIA;

EID: 0034071659     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003100-00013     Document Type: Article

References (23)

1. 1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725-1730.
2. 2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
3. 3. Autran B, Carcelain C, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
4. 4. Foudraine NA, Hovenkamp E, Notermans DW, et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13:177-184.
5. 5. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
6. 6. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999, 104:R13-R18.
7. 7. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999, 13:F79-F86.
8. 8. Harrigan PR, Whaley M, Montaner JSG. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999, 13:F59-F62.
9. 9. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 1999, 13:677-683.
10. 10. Phillips AN, McLean AR, Loveday C, et al. In vivo HIV-1 replicative capacity in early and advanced infection. AIDS 1999, 13:67-73.
11. 11. de Jong MD, de Boer RJ, de Wolf F, et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997, 11:F79-F84.
12. 12. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999, 340:1683-1684.
13. 13. Mulder J, Resnick R, Saget B, et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997, 35:1278-1280.
14. 14. Ibañez A, Puig T, Elias J, Clotet B, Ruiz L, Martinez M-A. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13:1045-1049.
15. 15. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243.
16. 16. Arno A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with < 250/μl CD4 T cells and undetectable plasma virus load. J Infect Dis 1999, 180:56-60.
17. 17. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
18. 18. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996, 271:1582-1586.
19. 19. Perelson AS, Essunger P, Cao Y. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
20. 20. Yerly S, Rakik A, De LS, et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998, 72:3520-3523.
21. 21. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
22. 22. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999, 5:518-525.
23. 23. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999, 73:797-800.